Chimeric Therapeutics Ltd

CHM

Company Profile

  • Business description

    Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.

  • Contact

    62 Lygon Street
    Level 3, Carlton
    MelbourneVIC3053
    AUS

    T: +61 398245254

    https://www.chimerictherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

Stocks News & Analysis

stocks

AI stocks post big gains in Q3. These are the winners and losers

Alphabet and Teradyne post big gains, while Salesforce and Adobe were down in the quarter.
stocks

12 picks for an income portfolio - Q3 2025 update

Fifteen months in and passive income growth has exceeded my target.
stocks

ASX’s only dividend aristocrat reports

Cyclical headwinds persist but loan book and industrial property prop up earnings.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,280.0038.90-0.42%
CAC 407,971.78109.76-1.36%
DAX 4024,378.290.51-0.00%
Dow JONES (US)46,694.9763.31-0.14%
FTSE 1009,479.1412.11-0.13%
HKSE26,957.77183.15-0.67%
NASDAQ22,941.67161.160.71%
Nikkei 22547,944.762,175.264.75%
NZX 50 Index13,445.2144.03-0.33%
S&P 5006,740.2824.490.36%
S&P/ASX 2008,981.4034.80-0.39%
SSE Composite Index3,882.7820.250.52%

Market Movers